Skip to main content

Oncolytics Biotech Value Stock - Dividend - Research Selection

Oncolytics Biotech

ISIN: CA6823108759, WKN: A2JMW5

Market price date: 28.05.2021
Market price: 3,69 CAD

Oncolytics Biotech Fundamental data and company key figures of the share

Annual reports in CAD
Key figures 10-03-2021
Cash flow
Net operating cash flow -22.068.400
Capital Expenditures -29.305
Free cash flow -22.097.704
Balance sheet
Total Equity 24.753.000
Liabilities & Shareholders equity 34.345.600
Income statement
Net income -22.505.100
Eps (diluted) -0,560
Diluted shares outstanding 46.167.000
Net sales/revenue 1

Fundamental ratios calculated on: 28-05-2021

Key figures 28-05-2021
Cash flow
P/C -7,72
P/FC -7,71
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization130.291.568,00 USD
Raw Data SourceIFRS in Millionen CAD
Stock Split2018-05-25,105.0000/1000.0000

Description of the company

Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,